Progyny Inc is a benefits management company that specializes in providing fertility and family-building benefits to employers and their employees. The company aims to improve the employee experience through comprehensive fertility solutions, including in vitro fertilization (IVF), egg freezing, and adoption services. Progyny partners with a network of fertility specialists to offer personalized care and support, helping individuals and couples navigate their family-building journeys. By focusing on innovative health services and a tailored approach, Progyny enhances the overall health and well-being of families while also addressing the financial implications of fertility treatments for employers. Read More
Fertility benefits company Progyny (NASDAQ:PGNY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 16.5% year on year to $324 million. The company expects next quarter’s revenue to be around $317.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.48 per share was 7.7% above analysts’ consensus estimates.
Fertility benefits company Progyny (NASDAQ:PGNY) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 16.5% year on year to $324 million. On top of that, next quarter’s revenue guidance ($317.5 million at the midpoint) was surprisingly good and 3.1% above what analysts were expecting. Its non-GAAP profit of $0.48 per share was 7.7% above analysts’ consensus estimates.
Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions
NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025.
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
As awareness around the need for expanded access and coverage of fertility grows, Progyny lifts off the conversation and provides a platform for the millions of individuals facing family building challenges
Let’s dig into the relative performance of Humana (NYSE:HUM) and its peers as we unravel the now-completed Q4 health insurance providers earnings season.
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, and The Broken Brown Egg, a nonprofit supporting BIPOC individuals and couples experiencing infertility, today announced the launch of their 2025 Awareness, Hope, and Activism (AHA) Grant, marking the fourth consecutive year of this family building partnership.
Even during a down period for the markets, Progyny has gone against the grain, climbing to $22.52. Its shares have yielded a 40% return over the last six months, beating the S&P 500 by 54.3%. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
The Russell 2000 is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential.
However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Alignment Healthcare (NASDAQ:ALHC) and the rest of the health insurance providers stocks fared in Q4.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Elevance Health (NYSE:ELV) and the rest of the health insurance providers stocks fared in Q4.
Exploring PROGYNY INC's Technical Signals and Breakout Potential: Based on good technical signals, PROGYNY INC is potentially setting up for a breakout.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers industry, including CVS Health (NYSE:CVS) and its peers.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare providers & services stocks, including McKesson (NYSE:MCK) and its peers.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers industry, including Cencora (NYSE:COR) and its peers.
Let’s dig into the relative performance of Clover Health (NASDAQ:CLOV) and its peers as we unravel the now-completed Q4 health insurance providers earnings season.
